Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
A Care network is a digital health network that connects healthcare stakeholders to deliver streamlined care with the patient at the centre of the experience
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated
